Abstract
The fungal burdens (number of CFU per pair of lungs) in mice infected with Aspergillus fumigatus AB16.4 (for which the amphotericin B [AMB] MIC was elevated) and W73355 (drug-susceptible parent) were reduced by 21 and 81%, respectively, after 5 days of AMB treatment (2 mg/kg/day), indicating that AB16.4 also shows reduced susceptibility to AMB in a murine pulmonary aspergillosis model.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 428-430 |
| Number of pages | 3 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 49 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2005 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint Dive into the research topics of 'In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B'. Together they form a unique fingerprint.
Cite this
Manavathu, E. K., Cutright, J. L., & Chandrasekar, P. H. (2005). In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B. Antimicrobial agents and chemotherapy, 49(1), 428-430. https://doi.org/10.1128/AAC.49.1.428-430.2005